Home > DNA Methyltransferase & > Azacitidine

Azacitidine

阿扎胞苷,氮杂胞苷,NSC 102816,NSC-102816,NSC102816 5-AzaC

Azacitidine 是胞苷的核苷类似物,通过捕获DNA甲基,特异性抑制DNA methylation(DNA甲基化)。

目录号
EY0611
EY0611
EY0611
纯度
99.33%
99.33%
99.33%
规格
100 mg
200 mg
500 mg
原价
160
310
720
售价
160
310
720
库存
现货
现货
现货
订购
订购
订购
订购
订购
订购
  • 生物活性

    5-Azacytidine (5-AZA), a cytidine analog,has been approved for the treatment of patients with acute myeloid leukemia(AML) and myelodyplastic syndrome (MDS). 5-Azacytidine is a potent growth inhibitor and a cytotoxic agent. DNA methyltransferase inhibitor. 5-Azacytidine acts as a demethylating agent by inhibiting DNA methyltransferase (Dnmt), forming covalent adducts with cellular DNMT1 depleting enzyme activity. Improves the efficiency of reprogramming of stem cells; induces differentiation of mesenchymal stem cells into cardiomyocytes.

  • 体外研究

  • 体内研究

    30% Propylene glycol, 5% Tween 80, 65% D5W(5%葡萄糖水溶液)

  • 激酶实验

  • 细胞实验

    Cell culture[1]


    The cells were cultured in DMEM with theF-12 Ham’s nutrient supplemented with 10% of foetal bovine serum (FBS) and 1%P/S/A solution. During the experiment, the cells were cultured under asepticand constant conditions in an incubator (37°C, 5% CO2 and 95%humidity). The media were changed every 2 days and the cells were passagedusing trypsin solution according to manufacturers’ instructions after reaching80% confluence.

    Pre-treatmentof ASCs with 5-AZA

    Prior experiment ASCs were seeded onto24-well plates at the density of 20 x 103 per well. After cell attachmentculture medium was replaced with medium containing 5-AZA (1μM).After total pre-treatment (48 h) with 5-AZA, cells were maintained in standardculture medium again. Cells cultured in standard medium (DMEM, 10% of FBS, 1% P/S/A)without addition of 5-AZA served as a control group. Non-treated cells servedas a control for comparison with the test culture. All experiments wereperformed after seventh day of experiment.

    Cellviability, population doubling time and colony forming unit-fibroblasts (CFU-fs)assay

    Cell proliferation rate was evaluated using10% resazurin-based dye-TOX-8 following manufacturer’s protocols. To performthe test, culturemedia were removed and replaced with culture medium containing 10% of the dye.The cells were then incubated with the dye in the CO2 incubator,37°C for 2 hrs. Supernatants were collected and transferred to 96-well plate toperform the spectrophotometric assay. The absorbance of the supernatants wasmeasured at a wavelength of 600 nm for resazurin, and 690 nm referencewavelength. Each measurement included a blank sample, containing medium withoutcells. The number of cells was estimated on the basis of standard curve,generated during the experiment. To prepare the curve, cells were seeded at thedensity of 20x 103, 40 x 103, 80 x103 per welland dye absorbance was measured in relation to certain cells number. Lineartrendline equation allowed estimating cells number throughout the experiment.

    Populationdoubling time (PDT) was assessed using formula presented below. Initialconcentration equaled 2 x 104 cells, (initial seeding density) whilefinal concentration equaled the number of cells in culture on the seventh dayof the experiment.



    To evaluate the ability of cells to formcolonies, ASCs were seeded in six-well plates at a density of 100 cells perwell and inoculated into a culture medium. The medium was changed every 2 daysand cultures were maintained for 7 days. After fixation in 4% ice-coldparaformaldehyde, cells were stained with pararosaniline solution and coloniesof more than 50 cells were counted and documented by a Power Shot Camera. Theefficiency of colony forming was calculated using the formula presented below.




  • 动物实验

    Animals[2]


    The C57BL/6 J mice (male, 6–8 weeks old,weighing 20–25 g) were fed with diet and water ad libitum under specificpathogen-free conditions and 12 h dark/light cycle.

    APAP-inducedtoxic hepatitis

    Toxic hepatitis was induced byintraperitoneal injection of APAP (350 mg/kg, dissolved in warm phosphatebuffered saline) in mice, vehicle or various doses of 5-AZA (1.25 mg/kg,2.5mg/kg, 5mg/kg, 10mg/kg, dissolved in normal saline, i.p.) was administered0.5 h prior to APAP exposure (n =8 per group). The animals were sacrificed by decapitationat 8 h after APAP exposure, blood and liver samples were harvested for furtherexperiments.

    Survivalanalysis

    To determine the effect of 5-AZA on themortality of APAP-exposed mice, lethal toxic hepatitis was induced byintraperitoneal injection of APAP (450 mg/kg), vehicle or 5-AZA (5 mg/kg) wasadministered 0.5 h prior to APAP exposure (n= 20 per group). The survival rateof these animals was assessed every 6 h for at least 7 days.

    Histologicalanalysis

    Formalin-fixed specimens were embedded inparaffin. Sections (4μm) were prepared and stained with hematoxylin & eosinroutinely for morphological evaluation under light microscope.

    Determinationof aminotransferases

    The ALT and AST activities in plasma wereassessed using the detection kits according to the manufacturer's instructions.



  • 不同实验动物依据体表面积的等效剂量转换表(数据来源于FDA指南)

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 AKm系数


    例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。


  • 参考文献

    [1] Kornicka K, Marycz K, Maredziak M, Tomaszewski KA, Nicpon J. The effects of the DNA methyltranfserases inhibitor 5-Azacitidine on ageing, oxidative stress and DNA methylation of adipose derived stem cells. J Cell Mol Med. 2017;21(2):387-401.
    [2] Yang C, Yi J, Gong X, et al. Anti-oxidative and anti-inflammatory benefits of the ribonucleoside analogue 5-azacitidine in mice with acetaminophen-induced toxic hepatitis. Int Immunopharmacol. 2017;48:91-95.
    [3] Broday, L., et al.: Mol. Cell Biol., 19, 3198 (1999)
    [4] Qian, X., et al.: Am. J. Pathol., 153, 1475 (1999)

    分子式
    C8H12N4O5
    分子量
    244.2
    CAS号
    320-67-2
    储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂(常温)
    DMSO
    49 mg/mL
    Water
    50 mg/mL
    Ethanol
    30 mg/mL

    体内溶解度
    24 mg/mL

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT00901537 Non-small Cell Lung Cancer|Squamous Cell Carcinoma of the Head and Neck Drug: Azacitidine and Cisplatin Loma Linda University Phase 1 2009-02-01 2014-06-02
    NCT01488565 Myelodysplastic Syndromes (MDS)|Acute Myeloid Leukaemia (AML) Drug: Azacitidine and eltrombopag Peter MacCallum Cancer Centre, Australia|GlaxoSmithKline|Celgene Corporation Phase 2 2010-12-01 2016-02-12
    NCT02940483 Brain Tumor Recurrent Drug: 5-Azacytidine The University of Texas Health Science Center, Houston Early Phase 1 2016-12-01 2016-12-09
    NCT01305460 Myelodysplastic Syndrome Drug: Azacitidine Groupe Francophone des Myelodysplasies Phase 1|Phase 2 2011-07-01 2015-10-28
    NCT02038816 Myelodysplastic Syndromes Drug: Deferasirox + Azacitidine|Drug: Azacitidine Sunnybrook Health Sciences Centre|Novartis Phase 2 2014-03-01 2014-01-15
    NCT02985190 MDS|Systemic Autoimmune Diseases Drug: Azacitidine Groupe Francophone des Myelodysplasies|Celgene Phase 2 2016-12-01 2016-12-02
    NCT01305135 High Grade Myelodysplastic Syndrome Lesions Drug: azacitidine and idarubicin Groupe Francophone des Myelodysplasies Phase 1|Phase 2 2010-12-01 2015-10-28
    NCT01379274 MDS Drug: Lenalidomide and azacitidine combination Rush University Medical Center|Celgene Corporation Phase 2 2011-01-01 2013-11-26
    NCT01537744 Solid Tumors|Virally Mediated Cancers and Liposarcoma Drug: oral 5-azacitidine in combination with romidepsin Sidney Kimmel Comprehensive Cancer Center|Celgene Corporation Phase 1 2012-02-01 2017-03-21
    NCT02323139 MDS Drug: Azacitidine and LDE255 Groupe Francophone des Myelodysplasies|Novartis Phase 1 2015-02-01 2016-05-30
    NCT01599325 Myelodysplastic Syndrome (MDS) Drug: Azacitidine Celgene Phase 2 2012-07-01 2017-01-30
    NCT01462578 Acute Myelocytic Leukemia|Myelodysplastic Syndrome Drug: Azacitidine Technische Universit盲t Dresden Phase 2 2011-09-01 2016-02-09
    NCT01324960 Myelodysplastic Syndromes Drug: Ceplene庐, IL-2, Azacitidine|Drug: Azacitidine Groupe Francophone des Myelodysplasies|EpiCept Corporation Phase 1|Phase 2 2011-03-01 2014-03-19
    NCT00795548 Myelodysplastic Syndrome|Acute Myeloid Leukemia Drug: 5-Azacitidine Heinrich-Heine University, Duesseldorf Phase 2 2008-11-01 2012-01-20
    NCT00413478 Chronic Lymphocytic Leukemia|Leukemia Drug: 5-Azacytidine M.D. Anderson Cancer Center|Celgene Corporation Phase 2 2006-09-01 2015-06-26
    NCT00387647 Leukemia Drug: Azacitidine H. Lee Moffitt Cancer Center and Research Institute|Celgene Corporation Phase 2 2006-08-01 2014-08-19
    NCT02196857 Leukemia Drug: Azacytidine|Drug: Sorafenib M.D. Anderson Cancer Center|Bayer Phase 2 2015-02-01 2017-03-09
    NCT01038635 Leukemia Drug: 5-Azacytidine|Drug: Lenalidomide M.D. Anderson Cancer Center|Celgene Phase 1|Phase 2 2009-12-01 2016-12-19
    NCT00350818 Myelodysplastic Syndrome|Leukemia Drug: Azacitidine M.D. Anderson Cancer Center|Celgene Corporation Phase 1 2005-10-01 2012-07-27
    NCT00721214 Myelodysplastic Syndrome Drug: 5-azacytidine Virginia Commonwealth University|Celgene Corporation Phase 2 2008-07-01 2016-02-03
    NCT01913951 Myelodysplastic Syndromes Drug: vosaroxin|Drug: Azacitidine Washington University School of Medicine Phase 1 2013-11-22 2017-02-18
    NCT00728520 Acute Myeloid Leukemia|Elderly Drug: Azacitidine Kansas City Veteran Affairs Medical Center Phase 2 2008-07-01 2008-08-05
    NCT01652781 Myelodysplastic Syndrome Drug: Azacitidine Seoul St. Mary's Hospital|Celgene Corporation Phase 2 2012-03-01 2015-11-18
    NCT02399917 Leukemia Drug: 5-azacytidine|Drug: Lirilumab|Behavioral: Phone Call M.D. Anderson Cancer Center|Bristol-Myers Squibb Phase 2 2015-04-01 2017-03-07

    注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 :
  • 收件地址 :
  • 电话号码 :
  • 单位名称 :
  • 产品货号 :
  • 产品规格 :
  • 发票抬头以及单位税号 :